Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, touches on emerging agents evaluated in patients with hormone receptor-positive (HR+) breast cancer, including AKT inhibitors and antibody-drug conjugates in the metastatic space, as well as oral selective estrogen receptor degraders (SERDs) in the early disease space. This interview took place during the 17th St. Gallen International Breast Cancer Conference.